0000000001140012

AUTHOR

Paolo Angelo Cortesi

showing 3 related works from this author

The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017 : a systematic analysis for the Global Bu…

2020

Background\ud \ud Cirrhosis and other chronic liver diseases (collectively referred to as cirrhosis in this paper) are a major cause of morbidity and mortality globally, although the burden and underlying causes differ across locations and demographic groups. We report on results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 on the burden of cirrhosis and its trends since 1990, by cause, sex, and age, for 195 countries and territories.\ud \ud \ud \ud Methods\ud \ud We used data from vital registrations, vital registration samples, and verbal autopsies to estimate mortality. We modelled prevalence of total, compensated, and decompensated cirrhosis on the bas…

Liver CirrhosisMaleCirrhosisCost-Benefit AnalysisHEPATITIS-BGlobal Burden of DiseaseLiver diseaseDisability Evaluation0302 clinical medicineBurden Global Mortality CirrhosisNon-alcoholic Fatty Liver DiseaseRisk FactorsFIBROSISEurope EasternPOPULATIONAged 80 and overeducation.field_of_studySingaporeMortality rate1. No povertyGastroenterologyHepatitis CHepatitis BMiddle AgedHepatitis BHepatitis C3. Good healthPREVALENCE030220 oncology & carcinogenesisAsia Central030211 gastroenterology & hepatologyEgyptFemaleQuality-Adjusted Life YearsViral hepatitisLife Sciences & BiomedicineAdultEUROPEPopulationGBD 2017 Cirrhosis CollaboratorsArticle03 medical and health sciencesLIVER-DISEASEmedicineHumanseducationLiver Diseases AlcoholicAfrica South of the SaharaAgedScience & TechnologyHepatologyGastroenterology & Hepatologybusiness.industryMORTALITYDISABILITYDECOMPENSATIONmedicine.diseaseYears of potential life lostEarly DiagnosisSocioeconomic Factors3121 General medicine internal medicine and other clinical medicineINJURIESHuman medicinebusinessDemographyRCLancet gastroenterology & hepatology
researchProduct

Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017

2020

Artículo con numerosos autores, sólo se mencionan el primero, los de la UAM y grupo colectivo

MaleLocal patternsDouble burdenBörnResearch & Experimental MedicineSjúkdómseinkenniDOUBLE BURDENChildhood overweightLífefnafræðiLæknisfræði0302 clinical medicineSyndemicChild11 Medical and Health Sciencesunder 5 years of ageGeneral Medicine3. Good healthGeographyMedicine Research & ExperimentalChild PreschoolIncomeGROWTHAFRICAmedicine.medical_specialtyBiochemistry & Molecular BiologyRJMedicinaImmunologyeducationMODELSwa_395General Biochemistry Genetics and Molecular BiologyArticleG03 medical and health sciencesHumansAuthor CorrectionDeveloping CountriesPovertyBiologyLBD Double Burden of Malnutrition CollaboratorsDemographyScience & TechnologyWasting SyndromePublic healthMORTALITYInfantNæringarskorturmedicine.diseaseObesityTRENDSsigns and symptomsSocial ClassRisk factorsSameindalíffræðiITC-ISI-JOURNAL-ARTICLEUNDERNUTRITIONHuman medicineClinical Medicine030217 neurology & neurosurgeryPediatric ObesityobesityOffitaÁhættuþættirGeographic MappingOverweightRA0421Global healthrisk factors030212 general & internal medicineSigns and symptomsWastingMalnutrition Global Burden of Diseases Global Nutrition low- and middle-income countries2. Zero hungerPublic health1. No povertyPublic Health Global Health Social Medicine and EpidemiologyA900 Others in Medicine and DentistryChildhood wastingPREVALENCEChemistryMappingFemaleLýðheilsamedicine.symptomLife Sciences & BiomedicineGROWTH FAILURENutritional StatusmalnutritionITC-HYBRIDws_115childrenEnvironmental healthmedicineErfðafræðiObesitywd_200MalnutritionInfant NewbornKlinisk medicinCell BiologyOverweightMalnutritionFolkhälsovetenskap global hälsa socialmedicin och epidemiologi3121 General medicine internal medicine and other clinical medicineNA
researchProduct

Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study

2016

Background & Aims: All oral direct acting antivirals (DAA) have been shown to improve the liver function of patients with decompensated cirrhosis but it is presently unknown whether this clinical improvement may lead to the delisting of some patients. The aim of this study was to assess if and which patients can be first inactivated due to clinically improvement and subsequently delisted in a real life setting. Methods: 103 consecutive listed patients without hepatocellular carcinoma were treated with different DAA combinations in 11 European centres between February 2014 and February 2015. Results: The cumulative incidence of inactivated and delisted patients by competing risk analysis…

Simeprevirmedicine.medical_specialtyCarcinoma HepatocellularCirrhosisWaiting ListsSofosbuvirmedicine.medical_treatmentDelistingLiver transplantationGastroenterologyDirect acting antivirals03 medical and health sciencesLiver disease0302 clinical medicineModel for End-Stage Liver DiseaseSDG 3 - Good Health and Well-beingInternal medicinemedicineHumansCumulative incidenceCirrhosiLiver transplantationHepatologybusiness.industryLiver Neoplasms[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyHepatitis C Chronicmedicine.disease3. Good healthCirrhosis030220 oncology & carcinogenesisHCV030211 gastroenterology & hepatologyDirect acting antiviralLiver functionbusinessmedicine.drug
researchProduct